Ocular Therapeutix (OCUL) Shares Outstanding (2013 - 2026)

Ocular Therapeutix has reported Shares Outstanding for 14 years, with the latest figure at $218.9 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding rose 37.44% year-over-year to $218.9 million; the trailing twelve-month figure through Mar 2026 stood at $218.9 million (up 37.44% YoY), and the FY2025 full-year result was $215.9 million, up 36.88% from the prior year.
• Shares Outstanding for Q1 2026 stood at $218.9 million, up from $215.9 million in the prior quarter.
• The five-year high for Shares Outstanding was $218.9 million in Q1 2026, with the low at $76.8 million in Q1 2022.
• Average Shares Outstanding over 5 years is $130.9 million, with a median of $154.7 million recorded in 2024.
• Year-over-year, Shares Outstanding advanced 0.53% in 2022 and soared 99.58% in 2024.
• Tracing OCUL's Shares Outstanding over 5 years: stood at $77.2 million in 2022, then surged by 48.91% to $115.0 million in 2023, then surged by 37.22% to $157.7 million in 2024, then soared by 36.88% to $215.9 million in 2025, then gained by 1.38% to $218.9 million in 2026.
• The last three Shares Outstanding figures came in at $218.9 million (Q1 2026), $215.9 million (Q4 2025), and $174.9 million (Q3 2025), per Business Quant data.

Peer Comparison